Patients with AML and other blood cancers need new medical treatment options. GMI-1271 has been tested via a Phase 1/2 clinical trial and was granted Breakthrough Therapy designation by the FDA for adults with relapsed or refractory AML.

Every year there are up to 100,000 hospital admissions for people with sickle cell disease. Rivipansel is currently being studied as a potential treatment for vaso-occlusive crisis, the primary trigger for hospitalizations related to sickle cell.

At GlycoMimetics, we actively conduct promising research

and seek to establish unique collaborations in our pursuit of new treatments for people with serious diseases.

Who We Are and What We Do

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.

GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Based on that technology, we have developed a robust, diversified product pipeline.

We are a public company, traded on the NASDAQ under the symbol GLYC. We are located in Rockville, Maryland in the BioHealth Capital Region.

Learn more.

Main navigation

Who We Are and What We Do

Footer